# Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome

> **NCT00169637** · PHASE3 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 14 (actual)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** rhGH

## Key facts

- **NCT ID:** NCT00169637
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00169637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00169637, "Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00169637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*